« Return to News | CROs/Service Providers

PharmaNet to Open Brazil Office

Thursday, February 19, 2009 09:00 AM

PharmaNet Development Group is expanding its presence in Latin America with the opening of a new office in Sao Paulo, Brazil.

The announcement of this new office comes just weeks after the contract research organization (CRO) signed a definitive merger agreement with private equity firm JLL Partners, a $250-million deal that will make the now public company a private CRO.

PharmaNet has provided clinical trial support in Latin America since 2002 with a network of staff in Brazil, Mexico and Peru and an office in Buenos Aires, Argentina, which opened in 2003.

"The number of clinical trials in Latin America has experienced significant growth over the past ten years," said Fernanda Duran, executive director, Latin American operations, in a company statement. "Our clients are more actively requesting Latin American sites in order to meet aggressive timelines for patient recruitment, thus bringing their new drugs to market sooner. I am thrilled about opening this office in Brazil which will enhance our infrastructure in the region."

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.